COMMUNIQUÉS West-GlobeNewswire

TRexBio Announces Pricing of Initial Public Offering
09/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]
Retension Pharmaceuticals Announces Pricing of Initial Public Offering
09/10/2026
FALLS CHURCH, Va., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Retension Pharmaceuticals, Inc. (Nasdaq: RTSN) (“Retension” or the “Company”), a clinical-stage biopharmaceutical company focused on developing medicines for the [...]
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
09/10/2026
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well- [...]
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
09/10/2026
Star ratings support Clover’s continued ability to offer market-leading and low out-of-pocket costs for members WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“ [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to [...]
Echosens to Address GLP-1 Costs and Metabolic Health at SIIA National Conference 2026, Highlight Opportunities for Self-Insured Stakeholders and On-Site Clinics
08/10/2026
WESTBOROUGH, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Echosens , a global leader in non-invasive liver diagnostics and maker of FibroScan®, announces that Shawn McGinnis, Director, Health Systems and Employer Markets, [...]
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
08/10/2026
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a [...]
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to [...]
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
08/10/2026
● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX [...]
Lakefront Receives Transparency Notification from Bank of America
08/10/2026
Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian [...]
Sienna Continues Platform Growth in Ontario
08/10/2026
MARKHAM, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Brighton Retirement [...]
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
08/10/2026
FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report [...]
Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
08/10/2026
Company is working to deploy 19-amino-acid detection into a developmental sequencing kit and remains confident in demonstrating detection of all 20 amino acids by year-end 2026 BRANFORD, Conn., Oct. 08, 2026 (GLOBE [...]
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
08/10/2026
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific [...]
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
08/10/2026
-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/10/2026
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors. [...]
Rua Bioscience and PharmAla Biotech partner to supply medicinal MDMA in New Zealand
08/10/2026
TAIRĀWHITI, New Zealand and TORONTO, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Rua Bioscience Limited (NZX: RUA) (“Rua”) and PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (“PharmAla”) announce that Rua and PharmAla [...]
Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference
08/10/2026
Previously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial New preclinical data evaluating NBD1 stabilizers in [...]
Initiation of buy-back programme
08/10/2026
ANNOUNCEMENT NO. 320 8 October 2026 The Board of Directors of ChemoMetec A/S has decided to buy back own shares based on the authorisation granted at the Annual General Meeting on 8 October 2026. The authorisation is [...]

Pages